Therefore, although the prolactin pathway is active in both SSM2 and SSM3 bone tumors, PrlR signaling is not sufficient to mediate the growth of ERα+/PR+ SSM3 cells in bones in the absence of ovarian hormones. Here, PRLR is linked to bone neoplasm.